Tirzepatide

GLP-1 meds like Ozempic or Mounjaro may reduce venous thromboembolism (VTE) risk by 20% in people with diabetes compared to other diabetes drugs, according to a study presented at the American Society of Hematology meeting.

Novo Holdings' $16.5 billion acquisition of Catalent aims to resolve Novo Nordisk's supply issues for weight-loss drugs, with plans to resell fill-finish sites to Novo Nordisk from 2026. Both companies expect the transaction to close by end of 2024. Despite investments in manufacturing capacity, Novo and Eli Lilly face potential market overestimation of demand for their weight-loss drugs, as evidenced by recent stock declines.

Eli Lilly plans to introduce Tirzepatide, marketed as Mounjaro, to India in 2025, targeting type 2 diabetes and obesity. The move aligns with the company's strategy to expand its portfolio in India, considering local affordability and value. Eli Lilly has been operating in India since 1993, collaborating with local firms for its diabetes portfolio, and aims to address India's growing healthcare challenges.

GLP-1 drugs like semaglutide and tirzepatide have expanded uses beyond diabetes and weight loss, potentially treating cardiovascular disease, kidney disease, anxiety, depression, and substance use disorder. CRISPR drugs Casgevy for sickle cell disease and β-thalassemia entered the market, though uptake is slow due to complex treatment processes. Protein-folding algorithms by Baker, Hassabis, and Jumper revolutionized biochemical research and pharmaceutical applications. ADCs received significant investment, with firms exploring new linker chemistries. Amylyx Pharmaceuticals pulled an ALS drug after trial failure, continuing research for other uses. Kelly Chibale called for recognizing African scientific potential. Virologists monitored H5N1, mpox, and Marburg outbreaks, with ongoing research and emergency measures. Radiopharmaceuticals saw increased investment and market growth. Evidence suggests vaccines like shingles and flu jabs may protect against dementia.

Eli Lilly plans to launch Tirzepatide (Mounjaro) in India in 2025, targeting type 2 diabetes and obesity. The company is optimistic about the Indian market due to rising disease burdens and health expenditure. Mounjaro's global Q3 2024 sales were over $3.1 billion, and pricing in India will be competitive, reflecting its efficacy.

Health experts warn of counterfeit weight loss meds sold online, containing dangerous substances like rat poison and causing life-threatening complications. Over 600 fake Ozempic pens seized in the UK since early 2023, with patients hospitalized. Authorities urge verification of pharmacies and collaboration to combat illegal operations.

Mounjaro, a weight loss drug, will be prioritized for high-need patients on the NHS over 12 years. It differs from Wegovy by mimicking two hormones, leading to greater weight loss. Eligibility includes those with a BMI of 30+ or 27+ with health issues. Slow rollout aims to protect other NHS services and ensure careful management. Public health implications include reducing obesity-related costs and risks, though concerns remain about addressing root causes and adequate support.

Eli Lilly's tirzepatide (Mounjaro, Zepbound) dominates the weight loss market, generating billions in sales. Competing with Novo Nordisk, Lilly's Zepbound showed superior weight loss results in studies, positioning it to potentially surpass Novo Nordisk's sales by 2025. However, challenges from compounding pharmacies and supply issues pose risks.

Eli Lilly to invest $3 billion in expanding Wisconsin manufacturing facility for injectable medicines like Zepbound and Mounjaro, adding 750 employees and involving 2,000 in construction. This move is part of a $23 billion drug production investment since 2020, driven by surging demand for GLP-1 drugs, leading to shortages and heavy investments by Lilly and Novo Nordisk.